Outcomes for patients with T-PLL treated with alemtuzumab alone or followed by autologous or allogeneic HSCT31
| . | Autograft . | Allograft . | All HSCT . | Controls* . |
|---|---|---|---|---|
| No. of cases | 15 | 13 | 28 | 23 |
| Median age, y (range) | 58 (43-68) | 51 (39-61) | 55 (39-68) | 64 (35-81) |
| Males:females | 8:7 | 10:3 | 18:10 | 16:7 |
| TRM rate, % | 7 | 31 | 18 | NA |
| Relapse rate, % | 60 | 33 | 48 | 96 |
| Median DFS, mo | 28 | 24 | 24 | 10 |
| Median OS, mo | 52 | 33 | 48 | 20 |
| 2-y OS rate, % | 78 | 62 | 71 | 31 |
| 5-y OS rate, % | 40 | 33 | 34 | 0 |
| . | Autograft . | Allograft . | All HSCT . | Controls* . |
|---|---|---|---|---|
| No. of cases | 15 | 13 | 28 | 23 |
| Median age, y (range) | 58 (43-68) | 51 (39-61) | 55 (39-68) | 64 (35-81) |
| Males:females | 8:7 | 10:3 | 18:10 | 16:7 |
| TRM rate, % | 7 | 31 | 18 | NA |
| Relapse rate, % | 60 | 33 | 48 | 96 |
| Median DFS, mo | 28 | 24 | 24 | 10 |
| Median OS, mo | 52 | 33 | 48 | 20 |
| 2-y OS rate, % | 78 | 62 | 71 | 31 |
| 5-y OS rate, % | 40 | 33 | 34 | 0 |
HSCT indicates hematopoietic stem cell transplant; TRM, transplant-related mortality; OS, overall survival; NA, not applicable; and DFS, disease-free survival.
Control group: patients who achieved CR and survived at least 6 months.